BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608. [PMID: 12584368 DOI: 10.1056/nejmoa020888] [Cited by in Crossref: 1450] [Cited by in F6Publishing: 365] [Article Influence: 76.3] [Reference Citation Analysis]
Number Citing Articles
1 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
2 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
3 Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015;64:1539-1545. [PMID: 25336114 DOI: 10.1136/gutjnl-2014-307883] [Cited by in Crossref: 186] [Cited by in F6Publishing: 158] [Article Influence: 23.3] [Reference Citation Analysis]
4 Minar P, Saeed SA, Afreen M, Kim MO, Denson LA. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2016;62:715-22. [PMID: 26551317 DOI: 10.1097/MPG.0000000000001029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
5 Campbell JP, Burton E, Wymer S, Shaw M, Vaughn BP. Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3336-43. [PMID: 29052818 DOI: 10.1007/s10620-017-4808-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med. 2015;21:730-738. [PMID: 26121193 DOI: 10.1038/nm.3897] [Cited by in Crossref: 132] [Cited by in F6Publishing: 117] [Article Influence: 18.9] [Reference Citation Analysis]
7 Boyer-Suavet S, Andreani M, Lateb M, Savenkoff B, Brglez V, Benzaken S, Bernard G, Nachman PH, Esnault V, Seitz-Polski B. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab. Front Immunol 2019;10:3069. [PMID: 31998325 DOI: 10.3389/fimmu.2019.03069] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
8 Grasmeier MK, Langmann AF, Langmann P, Treiber M, Thaler MA, Luppa PB. Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases. Therap Adv Gastroenterol 2021;14:17562848211037849. [PMID: 34434255 DOI: 10.1177/17562848211037849] [Reference Citation Analysis]
9 Marini JC, Sendecki J, Cornillie F, Popp JW Jr, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®. AAPS J 2017;19:161-71. [PMID: 27600137 DOI: 10.1208/s12248-016-9981-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
10 Sieper J. Developments in therapies for spondyloarthritis. Nat Rev Rheumatol 2012;8:280-7. [PMID: 22487798 DOI: 10.1038/nrrheum.2012.40] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
11 Scott FI, Lichtenstein GR. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Curr Treat Options Gastroenterol 2018;16:147-64. [PMID: 29492747 DOI: 10.1007/s11938-018-0177-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
12 Boyapati RK, Ho GT, Satsangi J. Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies? Clin Gastroenterol Hepatol 2017;15:76-8. [PMID: 27720912 DOI: 10.1016/j.cgh.2016.09.152] [Reference Citation Analysis]
13 Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:220-33. [PMID: 33249621 DOI: 10.1111/apt.16182] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, Hassan R, Pastan I. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. Mol Cancer Ther 2015;14:2789-96. [PMID: 26443804 DOI: 10.1158/1535-7163.MCT-15-0532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
15 de Vries HS, van Oijen MG, Driessen RJ, de Jong EM, Creemers MC, Kievit W, de Jong DJ. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011;71:7-19. [PMID: 21143496 DOI: 10.1111/j.1365-2125.2010.03760.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
16 Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139. [PMID: 20145610 DOI: 10.1038/ajg.2010.9] [Cited by in Crossref: 356] [Cited by in F6Publishing: 332] [Article Influence: 29.7] [Reference Citation Analysis]
17 Bagul A. Ischaemic/reperfusion injury: Role of infliximab. World J Transplant 2012; 2(3): 35-40 [PMID: 24175194 DOI: 10.5500/wjt.v2.i3.35] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, Schwartz DA, Wilson KT, Rosen MJ. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD. J Pediatr Gastroenterol Nutr 2014;58:213-9. [PMID: 24048170 DOI: 10.1097/MPG.0b013e3182a98df2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
19 Edlund H, Steenholdt C, Ainsworth MA, Goebgen E, Brynskov J, Thomsen OØ, Huisinga W, Kloft C. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration. AAPS J 2017;19:223-33. [PMID: 27739011 DOI: 10.1208/s12248-016-9989-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
20 Solehan HM, Said MS, Shaharir S, Rajalingham S. Rheumatoid arthritis: refractory to infliximab, a tumor necrosis factor inhibitor. J Clin Med Res 2011;3:270-4. [PMID: 22383918 DOI: 10.4021/jocmr630w] [Reference Citation Analysis]
21 Welles HC, Jennewein MF, Mason RD, Narpala S, Wang L, Cheng C, Zhang Y, Todd JP, Lifson JD, Balazs AB, Alter G, McDermott AB, Mascola JR, Roederer M. Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLoS Pathog 2018;14:e1007395. [PMID: 30517201 DOI: 10.1371/journal.ppat.1007395] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
22 Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20. [PMID: 16096329 DOI: 10.1136/ard.2005.040758] [Cited by in Crossref: 228] [Cited by in F6Publishing: 187] [Article Influence: 13.4] [Reference Citation Analysis]
23 Lew D, Yoon SM, Yan X, Robbins L, Haritunians T, Liu Z, Li D, McGovern DP. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients. World J Gastroenterol 2017; 23(40): 7265-7273 [PMID: 29142473 DOI: 10.3748/wjg.v23.i40.7265] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
24 Aybay C, Ozel S, Aybay C. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int 2006;26:473-80. [PMID: 16341700 DOI: 10.1007/s00296-005-0085-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
25 Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN; CDP870 Crohn's Disease Study Group. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96. [PMID: 18071721 DOI: 10.1007/s00384-007-0395-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
26 Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG. Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs 2017;77:363-77. [PMID: 28233275 DOI: 10.1007/s40265-017-0693-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
27 Osman M, Aaron S, Noga M, Yacyshyn E. Takayasu's arteritis progression on anti-TNF biologics: a case series. Clin Rheumatol 2011;30:703-6. [PMID: 21221688 DOI: 10.1007/s10067-010-1658-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
28 Malik PRV, Edginton AN. Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients. CPT Pharmacometrics Syst Pharmacol 2019;8:835-44. [PMID: 31343836 DOI: 10.1002/psp4.12456] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
29 Chaparro M, Andreu M, Barreiro-de Acosta M, García-Planella E, Ricart E, Domènech E, Esteve M, Merino O, Nos P, Peñalva M, Gisbert JP. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012; 18(37): 5219-5224 [PMID: 23066316 DOI: 10.3748/wjg.v18.i37.5219] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
30 Pascual V, Dieli-Crimi R, López-Palacios N, Bodas A, Medrano LM, Núñez C. Inflammatory bowel disease and celiac disease: Overlaps and differences. World J Gastroenterol 2014; 20(17): 4846-4856 [PMID: 24803796 DOI: 10.3748/wjg.v20.i17.4846] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
31 Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MN. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6:65-77. [PMID: 25729557 DOI: 10.1177/2040622314563929] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
32 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
33 Rahumatullah A, Lim TS, Yunus MH, Noordin R. Development of an Antigen Detection ELISA for Bancroftian Filariasis Using BmSXP-Specific Recombinant Monoclonal Antibody. Am J Trop Med Hyg 2019;101:436-40. [PMID: 31162018 DOI: 10.4269/ajtmh.19-0034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Li Z, Richards S, Surks HK, Jacobs A, Panzara MA. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol 2018;194:295-314. [PMID: 30144037 DOI: 10.1111/cei.13208] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
35 Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, Gentilini L, Bazzi P, Rizzello F, Coscia M. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301-8. [PMID: 18360638 DOI: 10.2147/tcrm.2007.3.2.301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
36 de Boer NKh, Löwenberg M, Hoentjen F. Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol 2014;7:83-92. [PMID: 24748811 DOI: 10.2147/CEG.S47627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Shah NB, Jolly JA, Horst SN, Peter M, Limper H, Zuckerman AD. Development of quality measures for use of self-injectable biologic therapy in inflammatory bowel disease: An integrated specialty pharmacy initiative. Am J Health Syst Pharm 2019;76:1296-304. [PMID: 31418790 DOI: 10.1093/ajhp/zxz142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
39 Ono K, Nimura S, Hideshima Y, Nabeshima K, Nakashima M. Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Exp Ther Med 2017;14:5485-90. [PMID: 29285080 DOI: 10.3892/etm.2017.5251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng 2021. [PMID: 33795852 DOI: 10.1038/s41551-021-00698-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
41 Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:i16-35. [PMID: 16481629 DOI: 10.1136/gut.2005.081950b] [Cited by in Crossref: 423] [Cited by in F6Publishing: 365] [Article Influence: 26.4] [Reference Citation Analysis]
42 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Giorgio V, Blasi E, Rigante D, Guerriero C, De Simone C, Fedele AL, Stella G, Gasbarrini A, Scaldaferri F. Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report. Int J Environ Res Public Health 2021;18:6711. [PMID: 34206410 DOI: 10.3390/ijerph18136711] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2927-36. [PMID: 23867874 DOI: 10.1097/MIB.0b013e31829aad16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
45 Vincenzi F, Bizzarri B, Ghiselli A, de’ Angelis N, Fornaroli F, de’ Angelis GL. Cystic fibrosis and Crohn’s disease: Successful treatment and long term remission with infliximab. World J Gastroenterol 2010; 16(15): 1924-1927 [PMID: 20397273 DOI: 10.3748/wjg.v16.i15.1924] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
46 Govani SM, Noureldin M, Higgins PDR, Heisler M, Saini SD, Stidham RW, Waljee JF, Waljee AK. Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. Am J Gastroenterol 2018;113:276-82. [PMID: 29231192 DOI: 10.1038/ajg.2017.438] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
47 Ternant D, Passot C, Aubourg A, Goupille P, Desvignes C, Picon L, Lecomte T, Mulleman D, Paintaud G. Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. Clin Pharmacokinet 2018;57:1173-84. [PMID: 29236229 DOI: 10.1007/s40262-017-0621-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
48 Vermeire S, Gils A. Value of drug level testing and antibody assays in optimising biological therapy. Frontline Gastroenterol 2013;4:41-3. [PMID: 23293739 DOI: 10.1136/flgastro-2012-100241] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
49 Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH. Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2018;7:e1424674. [PMID: 29721387 DOI: 10.1080/2162402X.2018.1424674] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
50 Angus HCK, Butt AG, Schultz M, Kemp RA. Intestinal Organoids as a Tool for Inflammatory Bowel Disease Research. Front Med (Lausanne) 2019;6:334. [PMID: 32010704 DOI: 10.3389/fmed.2019.00334] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
51 Mahapatro M, Erkert L, Becker C. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut. Cells 2021;10:111. [PMID: 33435303 DOI: 10.3390/cells10010111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
52 Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:224-33. [PMID: 26457382 DOI: 10.1097/MIB.0000000000000589] [Cited by in Crossref: 61] [Cited by in F6Publishing: 18] [Article Influence: 10.2] [Reference Citation Analysis]
53 Yadav A, Vasquez P, Dolgin NH, Falchuk KR, Feuerstein JD. Variations in Insurance Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD. J Clin Gastroenterol 2019;53:e239-42. [PMID: 30439759 DOI: 10.1097/MCG.0000000000001144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, Achdout H, Ghadially H, Dor Y, Nir T, Doviner V, Hershkovitz O, Mendelson M, Naparstek Y, Mandelboim O. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 2010;11:121-8. [PMID: 20023661 DOI: 10.1038/ni.1834] [Cited by in Crossref: 117] [Cited by in F6Publishing: 123] [Article Influence: 9.0] [Reference Citation Analysis]
55 Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545. [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 23.4] [Reference Citation Analysis]
56 Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10. [PMID: 32180822 DOI: 10.7573/dic.2019-10-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
57 Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol 2014;20:81-101. [PMID: 24705146 DOI: 10.4103/1319-3767.129473] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
58 Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3:63-68. [PMID: 25567472 DOI: 10.1093/gastro/gou087] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 6.9] [Reference Citation Analysis]
59 El-Matary W, Walters TD, Huynh HQ, deBruyn J, Mack DR, Jacobson K, Sherlock ME, Church P, Wine E, Carroll MW, Benchimol EI, Lawrence S, Griffiths AM. Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children. Inflamm Bowel Dis. 2019;25:150-155. [PMID: 29912413 DOI: 10.1093/ibd/izy217] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
60 Boysen M, Schlicksupp L, Dreher I, Loebbert R, Richter M. SEC Based Method for Size Determination of Immune Complexes of Therapeutic Antibodies in Animal Matrix. J Immunol Res 2016;2016:9096059. [PMID: 27556050 DOI: 10.1155/2016/9096059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
61 Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-1668.e3. [PMID: 30928454 DOI: 10.1016/j.cgh.2019.03.037] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 29.0] [Reference Citation Analysis]
62 Palmela C, Torres J, Cravo M. New Trends in Inflammatory Bowel Disease. GE Port J Gastroenterol 2015;22:103-11. [PMID: 28868386 DOI: 10.1016/j.jpge.2015.03.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
63 Gao SJ, Shi RH. Recent progress in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2012; 20(36): 3742-3747 [DOI: 10.11569/wcjd.v20.i36.3742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 2012;14:296-302. [PMID: 22407289 DOI: 10.1208/s12248-012-9340-y] [Cited by in Crossref: 189] [Cited by in F6Publishing: 169] [Article Influence: 18.9] [Reference Citation Analysis]
65 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
66 Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci 2012;57:1013-9. [PMID: 22089254 DOI: 10.1007/s10620-011-1969-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
67 Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24. [PMID: 12922952 DOI: 10.1136/ard.62.9.817] [Cited by in Crossref: 250] [Cited by in F6Publishing: 217] [Article Influence: 13.2] [Reference Citation Analysis]
68 Baran B, Karaca C. Practical medical management of Crohn's disease. ISRN Gastroenterol 2013;2013:208073. [PMID: 24307950 DOI: 10.1155/2013/208073] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
69 Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348-65. [PMID: 29431871 DOI: 10.1111/cei.13112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
70 Hemperly A, Vande Casteele N. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:929-42. [PMID: 29330783 DOI: 10.1007/s40262-017-0627-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
71 Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 2017;31:299-316. [PMID: 28612180 DOI: 10.1007/s40259-017-0231-8] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 32.8] [Reference Citation Analysis]
72 Tighe D, McNamara D. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 414-425 [PMID: 28210077 DOI: 10.3748/wjg.v23.i3.414] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
73 Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis. 2005;20:1-8. [PMID: 15459771 DOI: 10.1007/s00384-004-0634-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
74 Tabrizi M, Funelas C, Suria H. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J 2010;12:592-601. [PMID: 20652780 DOI: 10.1208/s12248-010-9220-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
75 Pansri P, Jaruseranee N, Rangnoi K, Kristensen P, Yamabhai M. A compact phage display human scFv library for selection of antibodies to a wide variety of antigens. BMC Biotechnol 2009;9:6. [PMID: 19175944 DOI: 10.1186/1472-6750-9-6] [Cited by in Crossref: 92] [Cited by in F6Publishing: 272] [Article Influence: 7.1] [Reference Citation Analysis]
76 Rajput R, Sharma G, Rawat V, Gautam A, Kumar B, Pattnaik B, Pradhan HK, Khanna M. Diagnostic Potential of Recombinant scFv Antibodies Generated Against Hemagglutinin Protein of Influenza A Virus. Front Immunol 2015;6:440. [PMID: 26388868 DOI: 10.3389/fimmu.2015.00440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
77 Ricart E, García-Bosch O, Ordás I, Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008; 14(36): 5523-5527 [PMID: 18810770 DOI: 10.3748/wjg.14.5523] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
78 van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, Dijkmans BA, Aarden LA. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007;66:253-6. [PMID: 16793840 DOI: 10.1136/ard.2006.057406] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 7.6] [Reference Citation Analysis]
79 Leung SO, Gao K, Wang GY, Cheung BK, Lee KY, Zhao Q, Cheung WT, Wang JZ. Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody. MAbs 2015;7:66-76. [PMID: 25427174 DOI: 10.4161/19420862.2014.985519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
80 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
81 Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27:185-198. [PMID: 19277912 DOI: 10.1007/s12032-009-9190-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
82 Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis. 2004;63:1120-1123. [PMID: 15115710 DOI: 10.1136/ard.2003.016451] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 4.3] [Reference Citation Analysis]
83 Hamze M, Meunier S, Karle A, Gdoura A, Goudet A, Szely N, Pallardy M, Carbonnel F, Spindeldreher S, Mariette X, Miceli-Richard C, Maillère B. Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors. Front Immunol 2017;8:500. [PMID: 28529511 DOI: 10.3389/fimmu.2017.00500] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
84 Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193-207. [PMID: 26130993 DOI: 10.5217/ir.2015.13.3.193] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
85 Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6:92-106. [PMID: 19153563 DOI: 10.1038/ncpgasthep1340] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
86 Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;9:101-111. [PMID: 29042821 DOI: 10.2147/cpaa.s138414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
87 Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn’s disease. Therap Adv Gastroenterol. 2010;3:179-189. [PMID: 21180600 DOI: 10.1177/1756283x09357579] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
88 Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, De Keyser F, Veys EM. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34. [PMID: 12922954 DOI: 10.1136/ard.62.9.829] [Cited by in Crossref: 110] [Cited by in F6Publishing: 93] [Article Influence: 5.8] [Reference Citation Analysis]
89 Shirvan AN, Aitken R. Isolation of recombinant antibodies directed against surface proteins of Clostridium difficile. Braz J Microbiol 2016;47:394-402. [PMID: 26991284 DOI: 10.1016/j.bjm.2016.01.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
90 González-Lama Y, Vera MI, Calvo M, Abreu L. [Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents]. Gastroenterol Hepatol 2010;33:449-60. [PMID: 20122758 DOI: 10.1016/j.gastrohep.2009.11.005] [Reference Citation Analysis]
91 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
92 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
93 Ungar B, Haj-Natour O, Kopylov U, Yavzori M, Fudim E, Picard O, Loebstein R, Lahat A, Maor Y, Avidan B, Lang A, Weiss B, Chowers Y, Eliakim R, Ben-Horin S. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. Medicine (Baltimore) 2015;94:e673. [PMID: 25950682 DOI: 10.1097/MD.0000000000000673] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
94 Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr Gastroenterol Rep 2009;11:509-17. [PMID: 19903428 DOI: 10.1007/s11894-009-0077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
95 Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs 2016;8:1407-16. [PMID: 27589009 DOI: 10.1080/19420862.2016.1216741] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
96 Ruppel J, Brady A, Elliott R, Leddy C, Palencia M, Coleman D, Couch JA, Wakshull E. Preexisting Antibodies to an F(ab')2 Antibody Therapeutic and Novel Method for Immunogenicity Assessment. J Immunol Res 2016;2016:2921758. [PMID: 27413757 DOI: 10.1155/2016/2921758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
97 Yogurtcu ON, Sauna ZE, McGill JR, Tegenge MA, Yang H. TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity. AAPS J 2019;21:96. [PMID: 31376048 DOI: 10.1208/s12248-019-0368-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
98 Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs 2021;35:715-33. [PMID: 34797516 DOI: 10.1007/s40259-021-00507-5] [Reference Citation Analysis]
99 Büning C, Lochs H. Conventional therapy for Crohn’s disease. World J Gastroenterol 2006; 12(30): 4794-4806 [PMID: 16937460 DOI: 10.3748/wjg.v12.i30.4794] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
100 Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3475-3484 [PMID: 24707130 DOI: 10.3748/wjg.v20.i13.3475] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
101 Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. [PMID: 29383030 DOI: 10.1177/1756283x17750355] [Cited by in Crossref: 90] [Cited by in F6Publishing: 35] [Article Influence: 22.5] [Reference Citation Analysis]
102 Kim HJ, Lee HE, Yu JW, Kil HR. Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities. Korean J Pediatr 2016;59:328-34. [PMID: 27610181 DOI: 10.3345/kjp.2016.59.8.328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Khodoun MV, Kucuk ZY, Strait RT, Krishnamurthy D, Janek K, Clay CD, Morris SC, Finkelman FD. Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis. J Allergy Clin Immunol 2013;132:1375-87. [PMID: 24139828 DOI: 10.1016/j.jaci.2013.09.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
104 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
105 Anderson P, Louie J, Lau A, Broder M. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005;7:3-9. [PMID: 15760575 DOI: 10.1007/s11926-005-0002-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
106 Kim YS. [How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?]. Korean J Gastroenterol 2018;71:74-80. [PMID: 29471604 DOI: 10.4166/kjg.2018.71.2.74] [Reference Citation Analysis]
107 Pękala A, Filip R, Aebisher D. Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study. J Clin Med 2021;10:2653. [PMID: 34208676 DOI: 10.3390/jcm10122653] [Reference Citation Analysis]
108 Pugliese D, Privitera G, Pizzolante F, Gasbarrini A, Guidi L, Armuzzi A. Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. Minerva Gastroenterol Dietol 2019;65:280-90. [PMID: 31646853 DOI: 10.23736/S1121-421X.19.02625-4] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
109 Meunier S, de Bourayne M, Hamze M, Azam A, Correia E, Menier C, Maillère B. Specificity of the T Cell Response to Protein Biopharmaceuticals. Front Immunol 2020;11:1550. [PMID: 32793213 DOI: 10.3389/fimmu.2020.01550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174. [PMID: 17121678 DOI: 10.1186/ar2084] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 7.2] [Reference Citation Analysis]
111 Yin H, Li X, Zhang B, Liu T, Yuan B, Ni Q, Hu S, Gu H. Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis. Immunology 2013;139:494-502. [PMID: 23480027 DOI: 10.1111/imm.12096] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
112 Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010;38:82-9. [PMID: 19565360 DOI: 10.1007/s12016-009-8140-3] [Cited by in Crossref: 125] [Cited by in F6Publishing: 101] [Article Influence: 10.4] [Reference Citation Analysis]
113 Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM. Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. J Crohns Colitis 2018;12:930-8. [PMID: 29697818 DOI: 10.1093/ecco-jcc/jjy050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
114 Sieczkowska J, Jarzębicka D, Meglicka M, Oracz G, Kierkus J. Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. Therap Adv Gastroenterol 2016;9:729-35. [PMID: 27582886 DOI: 10.1177/1756283X16650155] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
115 Rott S, Mrowietz U. Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ 2005;330:716-20. [PMID: 15790644 DOI: 10.1136/bmj.330.7493.716] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
116 Patel RN, Nigam GB, Jatale RG, Desai D, Makharia G, Ahuja V, Limdi JK. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol 2020;39:176-85. [PMID: 32483692 DOI: 10.1007/s12664-020-01047-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
117 Sack U, Emmrich F. [Monoclonal antibodies. Principles, generation, application, and side effects]. Internist (Berl) 2008;49:919-20, 921-4, 926-8. [PMID: 18587546 DOI: 10.1007/s00108-008-2055-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, Mikazane H, Lee YA, Smiyan S, Lim MJ, Kadinov V, Abud-Mendoza C, Kim H, Lee SJ, Bae Y, Kim S, Braun J. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017;76:346-54. [PMID: 27117698 DOI: 10.1136/annrheumdis-2015-208783] [Cited by in Crossref: 150] [Cited by in F6Publishing: 126] [Article Influence: 25.0] [Reference Citation Analysis]
119 Liu W, Saunders MJ, Bagia C, Freeman EC, Fan Y, Gawalt ES, Waggoner AS, Meng WS. Local retention of antibodies in vivo with an injectable film embedded with a fluorogen-activating protein. J Control Release 2016;230:1-12. [PMID: 27038493 DOI: 10.1016/j.jconrel.2016.03.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
120 Lundahl MLE, Fogli S, Colavita PE, Scanlan EM. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem Biol 2021;2:1004-20. [PMID: 34458822 DOI: 10.1039/d1cb00067e] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Azer SA, Azer S. What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. BMJ Open. 2018;8:e021233. [PMID: 30002009 DOI: 10.1136/bmjopen-2017-021233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
122 Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci 2020;13:743-51. [PMID: 32100960 DOI: 10.1111/cts.12760] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Patel MS, Miranda-Nieves D, Chen J, Haller CA, Chaikof EL. Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. Transl Res 2017;183:1-13. [PMID: 28034759 DOI: 10.1016/j.trsl.2016.11.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
124 Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015;9:806-815. [PMID: 26092578 DOI: 10.1093/ecco-jcc/jjv096] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 13.9] [Reference Citation Analysis]
125 O'Toole A, Moss AC. Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. Curr Gastroenterol Rep 2015;17:32. [PMID: 26188882 DOI: 10.1007/s11894-015-0453-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
126 Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10:301-16. [PMID: 20414204 DOI: 10.1038/nri2761] [Cited by in Crossref: 604] [Cited by in F6Publishing: 553] [Article Influence: 50.3] [Reference Citation Analysis]
127 Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010;12:217. [PMID: 21029481 DOI: 10.1186/ar3147] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 6.1] [Reference Citation Analysis]
128 Weisshof R, El Jurdi K, Zmeter N, Rubin DT. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018;35:1746-1762. [PMID: 30374806 DOI: 10.1007/s12325-018-0795-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
129 Krieckaert CL, Bartelds GM, Wolbink GJ. Therapy: Immunogenicity of biologic therapies-we need tolerance. Nat Rev Rheumatol 2010;6:558-9. [PMID: 20882023 DOI: 10.1038/nrrheum.2010.153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
130 Park DI. Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res. 2016;14:15-20. [PMID: 26884730 DOI: 10.5217/ir.2016.14.1.15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
131 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
132 Antoni CE, Manger B. [Biologicals: a new therapeutic approach for inflammatory diseases]. Internist (Berl) 2004;45 Suppl 1:S31-7. [PMID: 15160244 DOI: 10.1007/s00108-004-1225-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
133 Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-1826. e2. [PMID: 21530748 DOI: 10.1053/j.gastro.2010.11.058] [Cited by in Crossref: 268] [Cited by in F6Publishing: 238] [Article Influence: 24.4] [Reference Citation Analysis]
134 Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther 2019;49:31-40. [PMID: 30411382 DOI: 10.1111/apt.14997] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
135 Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007;56:1181-3. [PMID: 17698862 DOI: 10.1136/gut.2006.115980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
136 Masui S, Yonezawa A, Izawa K, Hayakari M, Asakura K, Taniguchi R, Isa M, Shibata H, Yasumi T, Nishikomori R, Takita J, Matsubara K. Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report. J Pharm Health Care Sci 2019;5:9. [PMID: 31073411 DOI: 10.1186/s40780-019-0136-4] [Reference Citation Analysis]
137 Everett SM, Hamlin PJ. Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011;2:144-50. [PMID: 28839599 DOI: 10.1136/fg.2010.003566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
138 Patil SA, Rustgi A, Langenberg P, Cross RK. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci 2013;58:209-15. [PMID: 23014844 DOI: 10.1007/s10620-012-2323-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
139 Beeg M, Nobili A, Orsini B, Rogai F, Gilardi D, Fiorino G, Danese S, Salmona M, Garattini S, Gobbi M. A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. Sci Rep 2019;9:2064. [PMID: 30765716 DOI: 10.1038/s41598-018-37950-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
140 Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231. [PMID: 17229796 DOI: 10.1136/gut.2006.099978] [Cited by in Crossref: 419] [Cited by in F6Publishing: 387] [Article Influence: 27.9] [Reference Citation Analysis]
141 Ternant D, Mulleman D, Lauféron F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 2012;73:55-65. [PMID: 21692827 DOI: 10.1111/j.1365-2125.2011.04050.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
142 Augustsson J, Eksborg S, Ernestam S, Gullström E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1462-6. [PMID: 17502359 DOI: 10.1136/ard.2007.070771] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
143 Ginard D, Mariño Z. ¿Tengo que premedicar a todos los pacientes cuando les pongo infliximab para disminuir las reacciones infusionales y/o la inmunogenicidad? Gastroenterología y Hepatología 2008;31:542-3. [DOI: 10.1157/13127101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
144 Hendy P, Hart A, Irving P. Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. Frontline Gastroenterol 2016;7:122-8. [PMID: 28839846 DOI: 10.1136/flgastro-2014-100527] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
145 Bender NK, Heilig CE, Dröll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27:269-274. [PMID: 17006705 DOI: 10.1007/s00296-006-0183-7] [Cited by in Crossref: 106] [Cited by in F6Publishing: 102] [Article Influence: 6.6] [Reference Citation Analysis]
146 Colman RJ, Xiong Y, Mizuno T, Hyams JS, Noe JD, Boyle B, D'Haens GR, van Limbergen J, Chun K, Yang J, Rosen MJ, Denson LA, Vinks AA, Minar P. Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Aliment Pharmacol Ther 2021. [PMID: 34935161 DOI: 10.1111/apt.16733] [Reference Citation Analysis]
147 Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol. 2010;3:31-42. [PMID: 21180588 DOI: 10.1177/1756283x09354136] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
148 Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231] [Reference Citation Analysis]
149 Andrick BJ, Schwab AI, Cauley B, O'Donnell LA, Meng WS. Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins. PLoS One 2015;10:e0135451. [PMID: 26270649 DOI: 10.1371/journal.pone.0135451] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
150 Joshi SR, Khan DA. Anaphylaxis Induced by Biologics. Curr Treat Options Allergy 2019;6:125-41. [DOI: 10.1007/s40521-019-00207-0] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
151 Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet 2017;56:1513-23. [PMID: 28353055 DOI: 10.1007/s40262-017-0535-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
152 Najarian DR, Hilton K, McCauley T, Qiu Y. A comparison study of bioanalytical methods for detection and characterization of anti-velaglucerase alfa antibodies. Bioanalysis 2017;9:775-86. [PMID: 28453301 DOI: 10.4155/bio-2016-0274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
154 Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:99-106. [PMID: 21180594 DOI: 10.1177/1756283x09356872] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
155 Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, Gill S. Bispecific Antibodies in the Treatment of Hematologic Malignancies. Clin Pharmacol Ther 2019;106:781-91. [PMID: 30770546 DOI: 10.1002/cpt.1396] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
156 Cappello M, Morreale GC. The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol. 2016;9:51-62. [PMID: 27656094 DOI: 10.4137/cgast.s38203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
157 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
158 Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol 2012;56:536-43. [PMID: 23053631 DOI: 10.1007/s10384-012-0182-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
159 Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. [PMID: 17299059 DOI: 10.1136/gut.2006.106781] [Cited by in Crossref: 649] [Cited by in F6Publishing: 609] [Article Influence: 43.3] [Reference Citation Analysis]
160 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
161 Park KT, Crandall WV, Fridge J, Leibowitz IH, Tsou M, Dykes DM, Hoffenberg EJ, Kappelman MD, Colletti RB. Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis 2014;20:946-51. [PMID: 24451222 DOI: 10.1097/01.MIB.0000441349.40193.aa] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
162 Bohra A, Rizvi QAA, Keung CYY, Vasudevan A, van Langenberg DR. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. World J Gastroenterol 2020; 26(36): 5437-5449 [PMID: 33024395 DOI: 10.3748/wjg.v26.i36.5437] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
163 Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
164 Bell RD, Moriarty KJ. Synchronous colonic lymphoma and adenocarcinoma in a patient with Crohn's disease, treated with thiopurine therapy and a TNFα inhibitor: a challenge to Occam's razor. BMJ Case Rep 2016;2016:bcr2015212464. [PMID: 26791118 DOI: 10.1136/bcr-2015-212464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Richardson SK, Gelfand JM. Update on the natural history and systemic treatment of psoriasis. Adv Dermatol 2008;24:171-96. [PMID: 19256309 DOI: 10.1016/j.yadr.2008.09.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
166 Picoraro J, Winberry G, Siegel CA, El-Matary W, Moses J, Grossman A, Park KT. Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. Inflamm Bowel Dis 2017;23:174-80. [PMID: 28002131 DOI: 10.1097/MIB.0000000000001002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
167 Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006;8:R131. [PMID: 16869978 DOI: 10.1186/ar2020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
168 van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164-172. [PMID: 23399692 DOI: 10.1038/nrrheum.2013.4] [Cited by in Crossref: 268] [Cited by in F6Publishing: 245] [Article Influence: 29.8] [Reference Citation Analysis]
169 Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, Rutgeerts P, Vermeire S. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721-1727. [PMID: 24474383 DOI: 10.1136/gutjnl-2012-304094] [Cited by in Crossref: 257] [Cited by in F6Publishing: 224] [Article Influence: 32.1] [Reference Citation Analysis]
170 Morais MR, Meneghello LP, de Oliveira CF, Carvalho AV. Late reaction to ustekinumab infusion. Dermatol Reports 2013;5:e2. [PMID: 25386321 DOI: 10.4081/dr.2013.e2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
171 Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:606-613. [PMID: 24552827 DOI: 10.1097/mib.0000000000000003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 5.9] [Reference Citation Analysis]
172 Chiu HY, Chu TW, Cheng YP, Tsai TF. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab. PLoS One 2015;10:e0142930. [PMID: 26566272 DOI: 10.1371/journal.pone.0142930] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
173 Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group., PSORT consortium. Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. J Invest Dermatol 2019;139:115-23. [PMID: 30130616 DOI: 10.1016/j.jid.2018.07.028] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
174 Kang E, Khalili A, Splawski J, Sferra TJ, Moses J. Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications. Pediatr Gastroenterol Hepatol Nutr 2018;21:329-35. [PMID: 30345247 DOI: 10.5223/pghn.2018.21.4.329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
175 Limdi JK, Shaffer JL. How "NICE" were we with infliximab? Inflamm Bowel Dis 2005;11:705-6. [PMID: 15973126 DOI: 10.1097/01.mib.0000169733.88645.da] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
176 Pintea I, Petricau C, Dumitrascu D, Muntean A, Branisteanu DC, Branisteanu DE, Deleanu D. Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review). Exp Ther Med 2021;22:949. [PMID: 34335891 DOI: 10.3892/etm.2021.10381] [Reference Citation Analysis]
177 Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself 2010;1:314-22. [PMID: 21487506 DOI: 10.4161/self.1.4.13904] [Cited by in Crossref: 200] [Cited by in F6Publishing: 178] [Article Influence: 25.0] [Reference Citation Analysis]
178 Nguyen DL, Flores S, Sassi K, Bechtold ML, Nguyen ET, Parekh NK. Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. Ther Adv Chronic Dis 2015;6:147-54. [PMID: 25954499 DOI: 10.1177/2040622315579621] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
179 Mulleman D, Lauféron F, Wendling D, Ternant D, Ducourau E, Paintaud G, Goupille P. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther 2011;13:R82. [PMID: 21639907 DOI: 10.1186/ar3350] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
180 Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M, Emery P, Gibofsky A, Kavanaugh AF, Keystone EC, Klareskog L, Russell AS, van de Putte LB, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis 2003;62 Suppl 2:ii2-9. [PMID: 14532138 DOI: 10.1136/ard.62.suppl_2.ii2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
181 Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 2005;7:R149-55. [PMID: 15642135 DOI: 10.1186/ar1465] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.7] [Reference Citation Analysis]
182 Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest Pharmacol Ther 2017; 8(3): 155-161 [PMID: 28828193 DOI: 10.4292/wjgpt.v8.i3.155] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
183 Ke Q, Kroger CJ, Clark M, Tisch RM. Evolving Antibody Therapies for the Treatment of Type 1 Diabetes. Front Immunol 2020;11:624568. [PMID: 33679717 DOI: 10.3389/fimmu.2020.624568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
184 Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:221-33. [PMID: 16901386 DOI: 10.1007/s11938-006-0041-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
185 Yarur AJ, Abreu MT. Back to the beginning: restarting infliximab in inflammatory bowel disease patients with prior loss of response. Clin Gastroenterol Hepatol 2014;12:1482-4. [PMID: 24735794 DOI: 10.1016/j.cgh.2014.04.011] [Reference Citation Analysis]
186 ten Hacken N, van der Vaart H, Koëter G, Kauffman H, Postma D. CORRESPONDENCE. Am J Respir Crit Care Med 2005;172:1608-1608. [DOI: 10.1164/ajrccm.172.12.1608] [Reference Citation Analysis]
187 McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4:883-898. [PMID: 23046232 DOI: 10.2217/imt.12.85] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
188 Ayyala US, Padilla ML. Diagnosis and treatment of hepatic sarcoidosis. Curr Treat Options Gastroenterol. 2006;9:475-483. [PMID: 17081481 DOI: 10.1007/s11938-006-0004-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
189 Lai Y, Wang R, Chen X, Tang D, Hu Y, Cai J, Zhang Q, Hu H. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). Hum Vaccin Immunother 2017;13:1-10. [PMID: 28301271 DOI: 10.1080/21645515.2017.1286433] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
190 Perry M, Abdullah A, Frleta M, MacDonald J, McGucken A. The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2020;12:1759720X20904850. [PMID: 32095163 DOI: 10.1177/1759720X20904850] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
191 Zitomersky NL, Atkinson BJ, Fournier K, Mitchell PD, Stern JB, Butler MC, Ashworth L, Hauenstein S, Heiner L, Chuang E, Singh S, Bousvaros A. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm Bowel Dis 2015;21:307-14. [PMID: 25569737 DOI: 10.1097/MIB.0000000000000284] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
192 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021;193:E1129-36. [PMID: 34312166 DOI: 10.1503/cmaj.202391] [Reference Citation Analysis]
193 Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8:E501-E507. [PMID: 17025268 DOI: 10.1208/aapsj080359] [Cited by in Crossref: 957] [Cited by in F6Publishing: 851] [Article Influence: 59.8] [Reference Citation Analysis]
194 Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, Wang X, Lyu Y, Chen X, Liu K, Yu AM, Zuo Z, Bi H. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B 2019;9:1113-44. [PMID: 31867160 DOI: 10.1016/j.apsb.2019.10.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
195 Demoor PA, Matusov Y, Kelly C, Kolan S, Barnachea L, Bazhenova LA. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. J Cancer 2011;2:153-64. [PMID: 21475720 DOI: 10.7150/jca.2.153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
196 Heads JT, Lamb R, Kelm S, Adams R, Elliott P, Tyson K, Topia S, West S, Nan R, Turner A, Lawson ADG. Electrostatic interactions modulate the differential aggregation propensities of IgG1 and IgG4P antibodies and inform charged residue substitutions for improved developability. Protein Eng Des Sel 2019;32:277-88. [PMID: 31868219 DOI: 10.1093/protein/gzz046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
197 Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F. Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. Biologics 2018;12:37-41. [PMID: 29430171 DOI: 10.2147/BTT.S145941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
198 Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS, Govindappa K, Green J, Griffiths CE, Holgate S, Jones D, Kimber I, Moggs J, Naisbitt DJ, Pirmohamed M, Reichmann G, Sims J, Subramanyam M, Todd MD, Van Der Laan JW, Weaver RJ, Park BK. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov 2013;12:306-24. [PMID: 23535934 DOI: 10.1038/nrd3974] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 10.1] [Reference Citation Analysis]
199 Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12(29): 4628-4635 [PMID: 16937430 DOI: 10.3748/wjg.v12.i29.4628] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
200 Yu L, Yang X, Xia L, Zhong J, Ge W, Wu J, Liu H, Liu F, Liu Z. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm 2015;2015:793764. [PMID: 25873771 DOI: 10.1155/2015/793764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
201 Shi YH, Weng Y, Liu ZJ. Detection of serum infliximab concentration for evaluation of treatment efficacy in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2015; 23(31): 4946-4953 [DOI: 10.11569/wcjd.v23.i31.4946] [Reference Citation Analysis]
202 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
203 Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-SanRomán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, García-Sepulcre MF, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. J Crohns Colitis 2021:jjab213. [PMID: 34864947 DOI: 10.1093/ecco-jcc/jjab213] [Reference Citation Analysis]
204 Thomas VA, Balthasar JP. Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies (Basel) 2019;8:E56. [PMID: 31817205 DOI: 10.3390/antib8040056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
205 Li M, Dai W, Yan W, Liu Y, Wang L, Li W. A dramatic response to a single dose of infliximab in a patient with prolonged pustular psoriasis derived from inverse psoriasis: Li et al. Dermatologic Therapy 2017;30:e12492. [DOI: 10.1111/dth.12492] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
206 Kuhbacher T, Fölsch U. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007; 13(8): 1149-1155 [PMID: 17451192 DOI: 10.3748/wjg.v13.i8.1149] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
207 Henry CA, Lyon RA, Ling H. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Vasc Health Risk Manag 2016;12:163-9. [PMID: 27143910 DOI: 10.2147/VHRM.S82387] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
208 Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55 Suppl 1:i36-i58. [PMID: 16481630 DOI: 10.1136/gut.2005.081950c] [Cited by in Crossref: 305] [Cited by in F6Publishing: 242] [Article Influence: 19.1] [Reference Citation Analysis]
209 Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004;63 Suppl 2:ii2-ii12. [PMID: 15479866 DOI: 10.1136/ard.2004.029272] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
210 Lord JD, Shows DM. Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease. World J Gastroenterol 2017; 23(18): 3240-3251 [PMID: 28566883 DOI: 10.3748/wjg.v23.i18.3240] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
211 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. Utilisation et incidence des agents biologiques à base d’anticorps monoclonaux durant la grossesse. CMAJ 2021;193:E1537-44. [PMID: 34607850 DOI: 10.1503/cmaj.202391-f] [Reference Citation Analysis]
212 Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, Tanpaiboon P, Mendelsohn NJ, Herskovitz E, Kronn D, Inbar-Feigenberg M, Ward-Melver C, Polan M, Gupta P, Rosenberg AS, Kishnani PS. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight 2017;2:94328. [PMID: 28814660 DOI: 10.1172/jci.insight.94328] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
213 Konrad A, Mähler M, Arni S, Flogerzi B, Klingelhöfer S, Seibold F. Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis 2005;20:9-17. [PMID: 15338166 DOI: 10.1007/s00384-004-0619-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
214 Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119:3011-23. [PMID: 19741298 DOI: 10.1172/JCI39065] [Cited by in Crossref: 216] [Cited by in F6Publishing: 151] [Article Influence: 16.6] [Reference Citation Analysis]
215 van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. Oncologist 2016;21:1260-8. [PMID: 27440064 DOI: 10.1634/theoncologist.2016-0061] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
216 Williams JV, Chen Z, Cseke G, Wright DW, Keefer CJ, Tollefson SJ, Hessell A, Podsiad A, Shepherd BE, Sanna PP, Burton DR, Crowe JE Jr, Williamson RA. A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. J Virol 2007;81:8315-24. [PMID: 17522220 DOI: 10.1128/JVI.00106-07] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
217 Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. [PMID: 17655372 DOI: 10.2165/00003088-200746080-00002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 11.1] [Reference Citation Analysis]
218 Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). Int J Nanomedicine 2007;2:39-47. [PMID: 17722511 DOI: 10.2147/nano.2007.2.1.39] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
219 Tran-Minh ML, Gornet JM, Maillet M, Houze P, Simon M, McLellan P, Hassid D, Vivier-Chicoteau J, Baudry C, Hammoudi N, Allez M. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study. J Crohns Colitis 2021;15:742-8. [PMID: 33205193 DOI: 10.1093/ecco-jcc/jjaa231] [Reference Citation Analysis]
220 . Antibody-mediated blockade of interferon-γ for the treatment of Crohn’s disease and psoriasis. Expert Opinion on Therapeutic Patents 2005;14:1373-8. [DOI: 10.1517/13543776.14.9.1373] [Reference Citation Analysis]
221 Song YN, Zheng P, Xiao JH, Lu ZJ. Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials. Eur J Clin Pharmacol 2014;70:907-14. [PMID: 24880961 DOI: 10.1007/s00228-014-1702-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
222 Chernajovsky Y. The importance of understanding the molecular mechanisms of resistance to biologics. Rheumatology (Oxford) 2012;51:397-8. [PMID: 21984767 DOI: 10.1093/rheumatology/ker313] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
223 Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7. [PMID: 15485995 DOI: 10.1136/ard.2004.030452] [Cited by in Crossref: 147] [Cited by in F6Publishing: 144] [Article Influence: 8.2] [Reference Citation Analysis]
224 Eshuis EJ, Bemelman WA, van Bodegraven AA, Sprangers MA, Bossuyt PM, van Milligen de Wit AW, Crolla RM, Cahen DL, Oostenbrug LE, Sosef MN, Voorburg AM, Davids PH, van der Woude CJ, Lange J, Mallant RC, Boom MJ, Lieverse RJ, van der Zaag ES, Houben MH, Vecht J, Pierik RE, van Ditzhuijsen TJ, Prins HA, Marsman WA, Stockmann HB, Brink MA, Consten EC, van der Werf SD, Marinelli AW, Jansen JM, Gerhards MF, Bolwerk CJ, Stassen LP, Spanier BW, Bilgen EJ, van Berkel AM, Cense HA, van Heukelem HA, van de Laar A, Slot WB, Eijsbouts QA, van Ooteghem NA, van Wagensveld B, van den Brande JM, van Geloven AA, Bruin KF, Maring JK, Oldenburg B, van Hillegersberg R, de Jong DJ, Bleichrodt R, van der Peet DL, Dekkers PE, Goei TH, Stokkers PC. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). BMC Surg 2008;8:15. [PMID: 18721465 DOI: 10.1186/1471-2482-8-15] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
225 Verhulst S, Best J, Syn WK, Reynaert H, Hellemans KH, Canbay A, Dolle L, van Grunsven LA. Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice. Sci Rep 2016;6:36586. [PMID: 27824131 DOI: 10.1038/srep36586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
226 Isaacs JD. Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther 2009;11:225. [PMID: 19490600 DOI: 10.1186/ar2594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
227 Shah NB, Haydek J, Slaughter J, Ashton JR, Zuckerman AD, Wong R, Raffa F, Garrett A, Duley C, Annis K, Wagnon J, Gaines L, Dalal R, Scoville E, Beaulieu DB, Schwartz D, Horst SN. Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:314-20. [PMID: 31671188 DOI: 10.1093/ibd/izz253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
228 Zeidan AM, Deangelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. [DOI: 10.1007/s00277-021-04734-2] [Reference Citation Analysis]
229 Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: Results of a systematic review. World J Gastroenterol 2013; 19(27): 4344-4350 [PMID: 23885145 DOI: 10.3748/wjg.v19.i27.4344] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
230 Scott FI, Lichtenstein GR. Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2014;12:59-75. [PMID: 24452768 DOI: 10.1007/s11938-013-0004-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
231 Pallagi-Kunstár &, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 2014; 20(17): 5031-5035 [PMID: 24833846 DOI: 10.3748/wjg.v20.i17.5031] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
232 Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108:40-7; quiz 48. [PMID: 23147525 DOI: 10.1038/ajg.2012.363] [Cited by in Crossref: 243] [Cited by in F6Publishing: 224] [Article Influence: 24.3] [Reference Citation Analysis]
233 Weksler ME. The immunotherapy of Alzheimer's disease. Immun Ageing 2004;1:2. [PMID: 15679923 DOI: 10.1186/1742-4933-1-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
234 Mulleman D, Méric JC, Paintaud G, Ducourau E, Magdelaine-Beuzelin C, Valat JP, Goupille P; Centre National de la Recherche Scientifique UMR 6239 GICC. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 2009;11:R178. [PMID: 19939280 DOI: 10.1186/ar2867] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
235 Brest P, Corcelle EA, Cesaro A, Chargui A, Belaïd A, Klionsky DJ, Vouret-Craviari V, Hebuterne X, Hofman P, Mograbi B. Autophagy and Crohn’s disease: at the crossroads of infection, inflammation, immunity, and cancer. Curr Mol Med. 2010;10:486-502. [PMID: 20540703 DOI: 10.2174/156652410791608252] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
236 Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2007;1:89-100. [PMID: 19072438 DOI: 10.1586/17474124.1.1.89] [Reference Citation Analysis]
237 Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, Chen L, Xie F, Curtis JR, Lewis JD. Comparative effectiveness of infliximab and adalimumab for Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:811-817.e3. [PMID: 23811254 DOI: 10.1016/j.cgh.2013.06.010] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
238 Krishnamurthy VR, Sardar MY, Ying Y, Song X, Haller C, Dai E, Wang X, Hanjaya-Putra D, Sun L, Morikis V, Simon SI, Woods RJ, Cummings RD, Chaikof EL. Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo. Nat Commun 2015;6:6387. [PMID: 25824568 DOI: 10.1038/ncomms7387] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
239 Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 2014;28:807-18. [PMID: 25488786 DOI: 10.1016/j.berh.2014.10.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
240 Townsend CM, Nguyen TM, Cepek J, Abbass M, Parker CE, MacDonald JK, Khanna R, Jairath V, Feagan BG. Adalimumab for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2020;5:CD012877. [PMID: 32413933 DOI: 10.1002/14651858.CD012877.pub2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
241 Nahra V, Hasbani GE, Chaaya M, Uthman I. The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review. Mediterr J Rheumatol 2020;31:400-5. [PMID: 33521572 DOI: 10.31138/mjr.31.4.400] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
242 Gerke AK. Treatment of Sarcoidosis: A Multidisciplinary Approach. Front Immunol 2020;11:545413. [PMID: 33329511 DOI: 10.3389/fimmu.2020.545413] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
243 Lim AW, Panaccione R, Seow CH. Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease. Therap Adv Gastroenterol 2011;4:145-51. [PMID: 21694815 DOI: 10.1177/1756283X10382816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
244 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
245 Schultz HS, Reedtz-Runge SL, Bäckström BT, Lamberth K, Pedersen CR, Kvarnhammar AM; ABIRISK consortium. Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. PLoS One 2017;12:e0178544. [PMID: 28562666 DOI: 10.1371/journal.pone.0178544] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
246 Maillère B, Delluc S, Ravot G. [The prediction of immunogenicity of therapeutic proteins]. Med Sci (Paris) 2012;28:82-8. [PMID: 22289835 DOI: 10.1051/medsci/2012281021] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
247 Vultaggio A, Perlato M, Nencini F, Vivarelli E, Maggi E, Matucci A. How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies? Front Immunol 2021;12:765747. [PMID: 34790200 DOI: 10.3389/fimmu.2021.765747] [Reference Citation Analysis]
248 Chowers Y. Taking Crohn's disease personally. Rambam Maimonides Med J 2013;4:e0011. [PMID: 23908861 DOI: 10.5041/RMMJ.10111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Shen MZ, Li JX, Zhang XH, Xu LP, Wang Y, Liu KY, Huang XJ, Hong SD, Mo XD. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. Front Immunol 2021;12:749266. [PMID: 34621279 DOI: 10.3389/fimmu.2021.749266] [Reference Citation Analysis]
250 Fritz D, Timmermans WMC, van Laar JAM, van Hagen PM, Siepman TAM, van de Beek D, Brouwer MC. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm 2020;7:e847. [PMID: 32718952 DOI: 10.1212/NXI.0000000000000847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
251 Swaminath A, Taunk R, Lawlor G. Use of methotrexate in inflammatory bowel disease in 2014: A User’s Guide. World J Gastrointest Pharmacol Ther 2014; 5(3): 113-121 [PMID: 25133040 DOI: 10.4292/wjgpt.v5.i3.113] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
252 Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:518-23. [PMID: 14602063 DOI: 10.1007/s11894-003-0043-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
253 Bravo F, Macpherson JA, Slack E, Patuto N, Cahenzli J, McCoy KD, Macpherson AJ, Juillerat P; SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. Clin Transl Gastroenterol 2021;12:e00298. [PMID: 33735154 DOI: 10.14309/ctg.0000000000000298] [Reference Citation Analysis]
254 Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010;55:1413-1420. [PMID: 19533357 DOI: 10.1007/s10620-009-0856-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
255 Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34. [PMID: 15388511 DOI: 10.1136/ard.2004.025130] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 5.7] [Reference Citation Analysis]
256 Subedi S, Gong Y, Chen Y, Shi Y. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019;13:2491-2502. [PMID: 31413544 DOI: 10.2147/dddt.s200147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
257 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
258 Ubah OC, Porter AJ, Barelle CJ. In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development. J Immunol Res 2020;2020:7283239. [PMID: 32090129 DOI: 10.1155/2020/7283239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
259 Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 2013;6:269-93. [PMID: 23814608 DOI: 10.1177/1756283X13479826] [Cited by in Crossref: 51] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
260 Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92; quiz e24. [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011] [Cited by in Crossref: 298] [Cited by in F6Publishing: 250] [Article Influence: 29.8] [Reference Citation Analysis]
261 Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics. 2008;2:763-777. [PMID: 19707457 DOI: 10.2147/btt.s3292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
262 Keino H, Okada AA, Watanabe T, Taki W. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease. Eye (Lond) 2014;28:1100-6. [PMID: 24946845 DOI: 10.1038/eye.2014.138] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
263 Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, Feagan BG. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol 2013;27:567-71. [PMID: 24106727 DOI: 10.1155/2013/327120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
264 Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol 2017;52:19-25. [PMID: 27665099 DOI: 10.1007/s00535-016-1266-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
265 Jabs DA. Immunosuppression for the Uveitides. Ophthalmology 2018;125:193-202. [PMID: 28942074 DOI: 10.1016/j.ophtha.2017.08.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 8.6] [Reference Citation Analysis]
266 Van Stappen T, Bollen L, Vande Casteele N, Papamichael K, Van Assche G, Ferrante M, Vermeire S, Gils A. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. Clin Transl Gastroenterol. 2016;7:e206. [PMID: 27929524 DOI: 10.1038/ctg.2016.62] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
267 Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44. [PMID: 15899030 DOI: 10.1186/ar1693] [Cited by in Crossref: 160] [Cited by in F6Publishing: 141] [Article Influence: 9.4] [Reference Citation Analysis]
268 Eekman DA, Hoyer MJ, van Vugt RM, Wolbink GJ, Mulder CJ, Dijkmans BA. Development of antibodies against humanized antitumor necrosis factor and loss of efficacy in a black spider monkey with inflammatory bowel disease. J Clin Rheumatol 2009;15:39. [PMID: 19125133 DOI: 10.1097/RHU.0b013e318195b211] [Reference Citation Analysis]
269 Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm 2014;2014:172821. [PMID: 24757282 DOI: 10.1155/2014/172821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
270 Stoll ML, Gotte AC. Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics 2008;2:229-52. [PMID: 19707357 DOI: 10.2147/btt.s2210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
271 Strauch U, Schölmerich J. Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs 2010;15:309-22. [PMID: 20402560 DOI: 10.1517/14728214.2010.480972] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
272 Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Coelho R, Tavares P, Soares J, Sousa AL, Carvalho D, Sousa P, da Silva JP, Meira T, Silva Ferreira F, Dias CC, Chowers Y, Ben-Horin S, Magro F; on behalf Portuguese IBD Study Group (GEDII). Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. Therap Adv Gastroenterol 2016;9:781-94. [PMID: 27803733 DOI: 10.1177/1756283X16658223] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
273 Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004;6:R535-43. [PMID: 15535831 DOI: 10.1186/ar1440] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 4.8] [Reference Citation Analysis]
274 Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut. 2005;54:890. [PMID: 15888806 DOI: 10.1136/gut.2005.065417] [Cited by in Crossref: 111] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
275 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
276 Matsuoka K, Hamada S, Shimizu M, Nanki K, Mizuno S, Kiyohara H, Arai M, Sugimoto S, Iwao Y, Ogata H, Hisamatsu T, Naganuma M, Kanai T, Mochizuki M, Hashiguchi M. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.PLoS One. 2018;13:e0204632. [PMID: 30286108 DOI: 10.1371/journal.pone.0204632] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
277 Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study. World J Gastroenterol 2007; 13(16): 2328-2332 [PMID: 17511032 DOI: 10.3748/wjg.v13.i16.2328] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
278 Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, Keystone EC, Schiff MH, van Riel PL, Weinblatt ME, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006;65 Suppl 3:iii2-15. [PMID: 17038465 DOI: 10.1136/ard.2006.061937] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
279 Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology 2016;5:e118. [PMID: 28090320 DOI: 10.1038/cti.2016.75] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
280 Heninger AK, Wentrup S, Al-Saeedi M, Schiessling S, Giese T, Wartha F, Meuer S, Schröder-Braunstein J. Immunomodulation of human intestinal T cells by the synthetic CD80 antagonist RhuDex®. Immun Inflamm Dis 2014;2:166-80. [PMID: 25505551 DOI: 10.1002/iid3.34] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
281 Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005;64 Suppl 2:ii78-82. [PMID: 15708944 DOI: 10.1136/ard.2004.034157] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
282 Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20:1996-2003. [PMID: 25192499 DOI: 10.1987/mib.0000000000000156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
283 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
284 Ananthakrishnan AN, Kane SV. The Toronto consensus guidelines for nonhospitalized ulcerative colitis: a welcome update but not the end of the story. Gastroenterology 2015;148:877-80. [PMID: 25805424 DOI: 10.1053/j.gastro.2015.03.025] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
285 Beeg M, Burti C, Allocati E, Ciafardini C, Banzi R, Nobili A, Caprioli F, Garattini S, Gobbi M. Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients' sera. Sci Rep 2021;11:14976. [PMID: 34294782 DOI: 10.1038/s41598-021-94431-x] [Reference Citation Analysis]
286 Ono K, Nimura S, Nishinakagawa T, Hideshima Y, Enjyoji M, Nabeshima K, Nakashima M. Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Exp Ther Med 2014;7:573-8. [PMID: 24520247 DOI: 10.3892/etm.2013.1456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
287 Komaki Y, Komaki F, Sakuraba A, Cohen R. Approach to Optimize Anti-TNF-α Therapy in Patients With IBD. Curr Treat Options Gastroenterol. 2016;14:83-90. [PMID: 26872815 DOI: 10.1007/s11938-016-0079-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
288 Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921-926. [PMID: 17301106 DOI: 10.1136/ard.2006.065615] [Cited by in Crossref: 379] [Cited by in F6Publishing: 341] [Article Influence: 25.3] [Reference Citation Analysis]
289 Pelletier AL, Nicaise-Roland P. Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease. World J Pharmacol 2016; 5(1): 44-50 [DOI: 10.5497/wjp.v5.i1.44] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
290 Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798-805. [PMID: 17417731 DOI: 10.1007/s10620-006-9269-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
291 Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2015;67:624-32. [PMID: 25370912 DOI: 10.1002/acr.22510] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
292 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?Curr Opin Gastroenterol. 2019;35:302-310. [PMID: 30973355 DOI: 10.1097/MOG.0000000000000536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
293 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 311] [Article Influence: 97.5] [Reference Citation Analysis]
294 Nattiv R, Wojcicki JM, Garnett EA, Gupta N, Heyman MB. High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice. World J Gastroenterol 2012; 18(11): 1229-1234 [PMID: 22468086 DOI: 10.3748/wjg.v18.i11.1229] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
295 Tada M, Suzuki T, Ishii-Watabe A. Development and characterization of an anti-rituximab monoclonal antibody panel. MAbs 2018;10:370-9. [PMID: 29309213 DOI: 10.1080/19420862.2018.1424610] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
296 Adegbola SO, Sahnan K, Twum-Barima C, Iqbal N, Reza L, Lung P, Warusavitarne J, Tozer P, Hart A. Current review of the management of fistulising perianal Crohn's disease. Frontline Gastroenterol 2021;12:515-23. [PMID: 34712470 DOI: 10.1136/flgastro-2020-101489] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg 2007;20:269-81. [PMID: 20011423 DOI: 10.1055/s-2007-991026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
298 Lambert JLW, De Schepper S, Speeckaert R. Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review. J Clin Med 2021;10:1040. [PMID: 33802483 DOI: 10.3390/jcm10051040] [Reference Citation Analysis]
299 Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138-44. [PMID: 16492717 DOI: 10.1136/gut.2005.079434] [Cited by in Crossref: 119] [Cited by in F6Publishing: 94] [Article Influence: 7.4] [Reference Citation Analysis]
300 Zittan E, Kabakchiev B, Milgrom R, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis. 2016;10:510-515. [PMID: 26783345 DOI: 10.1093/ecco-jcc/jjw014] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
301 Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, Sieper J. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis. 2007;66:419-421. [PMID: 16901959 DOI: 10.1136/ard.2006.054098] [Cited by in Crossref: 123] [Cited by in F6Publishing: 100] [Article Influence: 7.7] [Reference Citation Analysis]
302 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
303 Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. Clin Pharmacokinet 2015;54:1107-23. [PMID: 26123705 DOI: 10.1007/s40262-015-0296-9] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 10.5] [Reference Citation Analysis]
304 Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355-363. [PMID: 27130908 DOI: 10.1136/annrheumdis-2015-208786] [Cited by in Crossref: 175] [Cited by in F6Publishing: 154] [Article Influence: 29.2] [Reference Citation Analysis]
305 Lorenzin M, Ometto F, Ortolan A, Felicetti M, Favero M, Doria A, Ramonda R. An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Ther Adv Musculoskelet Dis 2020;12:1759720X20934277. [PMID: 32636944 DOI: 10.1177/1759720X20934277] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
306 Abreu MT. DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD. Dig Dis Sci 2019;64:3377-81. [PMID: 31628571 DOI: 10.1007/s10620-019-05796-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. Front Immunol 2020;11:1301. [PMID: 32695107 DOI: 10.3389/fimmu.2020.01301] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
308 Song S, Yang L, Trepicchio WL, Wyant T. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance. J Immunol Res 2016;2016:3072586. [PMID: 27340678 DOI: 10.1155/2016/3072586] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
309 Greenwald DA, Brandt LJ. Inflammatory Bowel Disease After Age 60. Curr Treat Options Gastroenterol. 2003;6:213-225. [PMID: 12744821 DOI: 10.1007/s11938-003-0003-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
310 de Vries HS, van Oijen MG, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 2008;31:1135-44. [PMID: 19026030 DOI: 10.2165/0002018-200831120-00009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
311 Ogrič M, Žigon P, Drobne D, Štabuc B, Sodin-Semrl S, Čučnik S, Praprotnik S. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels. Immunol Res 2018;66:726-36. [PMID: 30569379 DOI: 10.1007/s12026-018-9050-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
312 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
313 Khanna D, Mcmahon M, Furst DE. Safety of Tumour Necrosis Factor-?? Antagonists: . Drug Safety 2004;27:307-24. [DOI: 10.2165/00002018-200427050-00003] [Cited by in Crossref: 138] [Cited by in F6Publishing: 116] [Article Influence: 7.7] [Reference Citation Analysis]
314 Alt C, Lam JS, Harrison MT, Kershaw KM, Samuelsson S, Toll L, D'Andrea A. Nociceptin/orphanin FQ inhibition with SB612111 ameliorates dextran sodium sulfate-induced colitis. Eur J Pharmacol 2012;683:285-93. [PMID: 22449384 DOI: 10.1016/j.ejphar.2012.03.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
315 Guan Q, Ma Y, Hillman CL, Qing G, Ma AG, Weiss CR, Zhou G, Bai A, Warrington RJ, Bernstein CN. Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis. Mol Med. 2011;17:646-656. [PMID: 21424108 DOI: 10.2119/molmed.2010.00252] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
316 Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767-774. [PMID: 20811384 DOI: 10.1038/nrd3229] [Cited by in Crossref: 683] [Cited by in F6Publishing: 603] [Article Influence: 56.9] [Reference Citation Analysis]
317 Szymanska E, Dadalski M, Oracz G, Kierkus J. Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease. Prz Gastroenterol 2015;10:164-8. [PMID: 26516383 DOI: 10.5114/pg.2015.52298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
318 Yang S, Yang S, Kwon Jo Y, Kim S, Jung Chang M, Choi J, Hee Cheon J, Yu YM. Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021;12:20406223211041927. [PMID: 34729142 DOI: 10.1177/20406223211041927] [Reference Citation Analysis]
319 Talotta R, Berzi A, Atzeni F, Batticciotto A, Clerici M, Sarzi-Puttini P, Trabattoni D. Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response. J Clin Immunol. 2015;35:550-557. [PMID: 26271387 DOI: 10.1007/s10875-015-0182-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
320 Numakura T, Tamada T, Nara M, Muramatsu S, Murakami K, Kikuchi T, Kobayashi M, Muroi M, Okazaki T, Takagi S, Eishi Y, Ichinose M. Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn's disease during infliximab therapy. BMC Pulm Med 2016;16:30. [PMID: 26864464 DOI: 10.1186/s12890-016-0193-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
321 McLean LP, Cross RK. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol 2016;12:833-42. [PMID: 27096357 DOI: 10.1080/17425255.2016.1181171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
322 Marafini I, Di Fusco D, Calabrese E, Sedda S, Pallone F, Monteleone G. Antisense approach to inflammatory bowel disease: prospects and challenges. Drugs 2015;75:723-30. [PMID: 25911184 DOI: 10.1007/s40265-015-0391-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
323 Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7:e135. [PMID: 26741065 DOI: 10.1038/ctg.2015.63] [Cited by in Crossref: 236] [Cited by in F6Publishing: 216] [Article Influence: 39.3] [Reference Citation Analysis]
324 Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53:1485-1493. [PMID: 15361500 DOI: 10.1136/gut.2003.035253] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
325 Razmeh S, Niknam N, Sadat Rabbani N, Nikoee S, Vafa Pour F, Taghavian L. Cortical Vein Thrombosis after Infliximab Treatment for Crohn's Disease. Neurol Int 2021;13:120-4. [PMID: 33799515 DOI: 10.3390/neurolint13010011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 2006;65:746-752. [PMID: 16339288 DOI: 10.1136/ard.2005.045062] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 6.7] [Reference Citation Analysis]
327 Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 2004;63:144-8. [PMID: 14722202 DOI: 10.1136/ard.2003.015933] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
328 Iwamoto N, Yokoyama K, Takanashi M, Yonezawa A, Matsubara K, Shimada T. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum. Curr Pharm Biotechnol 2018;19:495-505. [PMID: 29968534 DOI: 10.2174/1389201019666180703093517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
329 Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014;53:213-22. [PMID: 23946436 DOI: 10.1093/rheumatology/ket260] [Cited by in Crossref: 127] [Cited by in F6Publishing: 111] [Article Influence: 14.1] [Reference Citation Analysis]
330 Colman RJ, Portocarrero-Castillo A, Chona D, Hellmann J, Minar P, Rosen MJ. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflamm Bowel Dis 2021;27:507-15. [PMID: 32426829 DOI: 10.1093/ibd/izaa108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
331 Rolandsdotter H, Marits P, Sundin U, Wikström AC, Fagerberg UL, Finkel Y, Eberhardson M. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment. Int J Mol Sci 2017;18:E575. [PMID: 28272355 DOI: 10.3390/ijms18030575] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
332 Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger CM, Chen L, Xie F, Curtis JR, Lewis JD. Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease. Clin Gastroenterol Hepatol. 2015;13:1293-1301.e5; quiz e70, e72. [PMID: 25724699 DOI: 10.1016/j.cgh.2015.02.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
333 Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1435-42. [PMID: 25590953 DOI: 10.1097/MIB.0000000000000312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
334 Saraceno R, Saggini A, Pietroleonardo L, Chimenti S. Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol 2009;2:27-37. [PMID: 21436966 DOI: 10.2147/ccid.s3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
335 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
336 Mayer A, Sharma SK, Tolner B, Minton NP, Purdy D, Amlot P, Tharakan G, Begent RH, Chester KA. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer 2004;90:2402-10. [PMID: 15162148 DOI: 10.1038/sj.bjc.6601888] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
337 Declerck P, Farouk Rezk M. The road from development to approval: evaluating the body of evidence to confirm biosimilarity. Rheumatology (Oxford) 2017;56:iv4-iv13. [PMID: 28903545 DOI: 10.1093/rheumatology/kex279] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
338 Löwenberg M. Is there a beneficial effect of adding azathioprine to adalimumab in Crohn's disease patients? Ann Transl Med 2018;6:278. [PMID: 30094264 DOI: 10.21037/atm.2018.06.36] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
339 Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600. [PMID: 15345498 DOI: 10.1136/ard.2004.020875] [Cited by in Crossref: 198] [Cited by in F6Publishing: 179] [Article Influence: 11.0] [Reference Citation Analysis]
340 De Santis S, Kunde D, Galleggiante V, Liso M, Scandiffio L, Serino G, Pinto A, Campiglia P, Sorrentino R, Cavalcanti E, Santino A, Caruso ML, Eri R, Chieppa M. TNFα deficiency results in increased IL-1β in an early onset of spontaneous murine colitis. Cell Death Dis 2017;8:e2993-e2993. [DOI: 10.1038/cddis.2017.397] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
341 Sharma SM, Fu DJ, Xue K. A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis. Ophthalmol Ther 2018;7:1-17. [PMID: 29189960 DOI: 10.1007/s40123-017-0115-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
342 Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007;67:2511-37. [PMID: 18034589 DOI: 10.2165/00003495-200767170-00005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
343 Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
344 Krieckaert CL, Lems WF. Are we ready for therapeutic drug monitoring of biologic therapeutics? Arthritis Res Ther 2011;13:120. [PMID: 21861867 DOI: 10.1186/ar3395] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
345 Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther 2018;47:229-37. [PMID: 29159893 DOI: 10.1111/apt.14421] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
346 Yamamoto-Furusho JK. Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies. Pharmgenomics Pers Med 2017;10:197-204. [PMID: 28603427 DOI: 10.2147/PGPM.S109648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
347 Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505-9. [PMID: 25101334 DOI: 10.1155/2014/967598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
348 Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol 2014;47:6-16. [PMID: 23345026 DOI: 10.1007/s12016-013-8359-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
349 Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009;3:183-91. [PMID: 19707407 DOI: 10.2147/btt.2009.3099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 18] [Article Influence: 0.1] [Reference Citation Analysis]
350 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
351 Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther. 2012;6:245-250. [PMID: 23055694 DOI: 10.2147/dddt.s25426] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
352 Caprioli F, Caruso R, Sarra M, Pallone F, Monteleone G. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol 2012;165:820-8. [PMID: 21806600 DOI: 10.1111/j.1476-5381.2011.01614.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
353 Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr Treat Options Gastro 2007;10:185-94. [DOI: 10.1007/s11938-007-0012-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
354 Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol 2016;137:1674-80. [PMID: 27130857 DOI: 10.1016/j.jaci.2016.02.015] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 20.7] [Reference Citation Analysis]
355 Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 2014;20:1996-2003. [PMID: 25192499 DOI: 10.1097/MIB.0000000000000156] [Cited by in Crossref: 142] [Cited by in F6Publishing: 54] [Article Influence: 20.3] [Reference Citation Analysis]
356 Sirotti S, Generali E, Ceribelli A, Isailovic N, De Santis M, Selmi C. Personalized medicine in rheumatology: the paradigm of serum autoantibodies. Auto Immun Highlights 2017;8:10. [PMID: 28702930 DOI: 10.1007/s13317-017-0098-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
357 Talotta R, Berzi A, Doria A, Batticciotto A, Ditto MC, Atzeni F, Sarzi-Puttini P, Trabattoni D. The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. Int J Mol Sci 2017;18:E2127. [PMID: 29023386 DOI: 10.3390/ijms18102127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
358 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
359 Karube H, Kamoi K, Ohno-Matsui K. Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet's disease. Int Med Case Rep J 2016;9:301-4. [PMID: 27729816 DOI: 10.2147/IMCRJ.S117731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
360 Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25. [PMID: 26795209 DOI: 10.1186/s13075-016-0930-4] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 15.7] [Reference Citation Analysis]
361 Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2014;(8):CD006884. [PMID: 25157445 DOI: 10.1002/14651858.cd006884.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
362 Qazi T, Shah B, El-Dib M, Farraye FA. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2016;61:589-96. [PMID: 26441281 DOI: 10.1007/s10620-015-3893-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
363 Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clin Pharmacokinet 2019;58:169-87. [PMID: 29802542 DOI: 10.1007/s40262-018-0680-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
364 Awwad S, Angkawinitwong U. Overview of Antibody Drug Delivery. Pharmaceutics 2018;10:E83. [PMID: 29973504 DOI: 10.3390/pharmaceutics10030083] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
365 Rocha C, Lago P, Fernandes S, Correia L, Portela F, Vieira AI, Patita M, Arroja B, Ministro P, Alves C, Dias CC, Magro F. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. Therap Adv Gastroenterol 2020;13:1756284820965790. [PMID: 33281935 DOI: 10.1177/1756284820965790] [Reference Citation Analysis]
366 Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014;16:22-6. [PMID: 24114449 DOI: 10.1208/s12248-013-9534-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
367 Yarur AJ, Jain A, Quintero MA, Czul F, Deshpande AR, Kerman DH, Abreu MT. Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy. J Clin Gastroenterol 2019;53:210-5. [PMID: 29517712 DOI: 10.1097/MCG.0000000000001002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
368 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
369 Guidi L, Ratto C, Semeraro S, Roberto I, De Vitis I, Papa A, Marzo M, Parello A, Foglietto G, Doglietto GB, Gasbarrini GB, Fedeli G. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol 2008;12:111-7. [PMID: 18545878 DOI: 10.1007/s10151-008-0411-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
370 Buhl SS, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open 2014;4:e005887. [PMID: 25524543 DOI: 10.1136/bmjopen-2014-005887] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
371 Segaert S. Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update. J Inflamm Res 2009;2:29-36. [PMID: 22096350 DOI: 10.2147/jir.s4405] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
372 Vande Casteele N, Khanna R. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res 2017;34:1556-63. [PMID: 28374338 DOI: 10.1007/s11095-017-2150-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
373 Coutinho de Sousa B, Reis Machado J, da Silva MV, da Costa TA, Lazo-Chica JE, Degasperi TD, Rodrigues Junior V, Sales-Campos H, Uber Bucek E, Freire Oliveira CJ. Morinda citrifolia (Noni) Fruit Juice Reduces Inflammatory Cytokines Expression and Contributes to the Maintenance of Intestinal Mucosal Integrity in DSS Experimental Colitis. Mediators Inflamm. 2017;2017:6567432. [PMID: 28194046 DOI: 10.1155/2017/6567432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
374 Paintaud G, Tonelli D, Postaire E; Round Table No 5, Giens XXII. Biotherapies: are they just like any other drugs? Therapie 2007;62:229-39. [PMID: 17803891 DOI: 10.2515/therapie:2007041] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
375 Sorrentino D. State-of-the-art medical prevention of postoperative recurrence of Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2013;10:413-422. [PMID: 23648935 DOI: 10.1038/nrgastro.2013.69] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
376 Ishida K, Inoue T, Fujiwara K, Sakanaka T, Narabayashi K, Nouda S, Okada T, Kakimoto K, Kuramoto T, Kawakami K, Abe Y, Takeuchi T, Murano M, Tokioka S, Umegaki E, Higuchi K. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol 2013; 19(17): 2676-2682 [PMID: 23674875 DOI: 10.3748/wjg.v19.i17.2676] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
377 Pérez I, Fernández L, Sánchez-Ramón S, Alba C, Zatarain A, Cañas M, López ON, Olivares D, Rey E, Taxonera C. Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels. Therap Adv Gastroenterol 2018;11:1756284818783613. [PMID: 30034528 DOI: 10.1177/1756284818783613] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
378 Osterman MT, Lichtenstein GR. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007;10:195-207. [PMID: 17547858 DOI: 10.1007/s11938-007-0013-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
379 Johnston EL, Warner BD, Digby-Bell JL, Unsworth N, Anderson S, Sanderson JD, Arkir Z, Irving PM. Utilisation of anti-TNF levels in a UK tertiary IBD centre. Frontline Gastroenterol 2017;8:189-95. [PMID: 28839908 DOI: 10.1136/flgastro-2016-100739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
380 Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014;2:333-44. [PMID: 25360311 DOI: 10.1177/2050640614550672] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
381 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
382 Nakae K, Masui S, Yonezawa A, Hashimoto M, Watanabe R, Murata K, Murakami K, Tanaka M, Ito H, Yokoyama K, Iwamoto N, Shimada T, Nakamura M, Denda M, Itohara K, Nakagawa S, Ikemi Y, Imai S, Nakagawa T, Hayakari M, Matsubara K. Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data. PLoS One 2021;16:e0258601. [PMID: 34644354 DOI: 10.1371/journal.pone.0258601] [Reference Citation Analysis]
383 Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, Rogler G, Biedermann L, Scharl M. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflamm Intest Dis 2021;6:38-47. [PMID: 33850838 DOI: 10.1159/000511296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
384 Stokkers PC, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:201-10. [PMID: 16901384 DOI: 10.1007/s11938-006-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
385 D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56:725-32. [PMID: 17440187 DOI: 10.1136/gut.2006.103564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
386 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
387 Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs. 2006;66:1431-1439. [PMID: 16906776 DOI: 10.2165/00003495-200666110-00002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
388 Sardar MYR, Mandhapati AR, Park S, Wever WJ, Cummings RD, Chaikof EL. Convergent Synthesis of Sialyl LewisX- O-Core-1 Threonine. J Org Chem 2018;83:4963-72. [PMID: 29638128 DOI: 10.1021/acs.joc.7b03117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
389 Sidiropoulos PI, Boumpas DT. Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:701-3. [PMID: 16699049 DOI: 10.1136/ard.2005.049890] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
390 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
391 Ducharme J, Pelletier C, Zacharias R. Premedications for infliximab infusions do not impact the risk of acute adverse drug reactions. Frontline Gastroenterol 2011;2:249-54. [PMID: 28839619 DOI: 10.1136/flgastro-2011-100030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
392 de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252-4. [PMID: 17472991 DOI: 10.1136/ard.2007.072397] [Cited by in Crossref: 104] [Cited by in F6Publishing: 88] [Article Influence: 6.9] [Reference Citation Analysis]
393 Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7:289-300. [PMID: 28839870 DOI: 10.1136/flgastro-2016-100685] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
394 Vande Casteele N. Assays for measurement of TNF antagonists in practice. Frontline Gastroenterol 2017;8:236-42. [PMID: 29067148 DOI: 10.1136/flgastro-2016-100692] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
395 Sieper J. Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment? Nat Rev Rheumatol 2008;4:398-9. [DOI: 10.1038/ncprheum0846] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
396 Busard CI, Menting SP, van Bezooijen JS, van den Reek JM, Hutten BA, Prens EP, de Jong EM, van Doorn MB, Spuls PI. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. Trials 2017;18:52. [PMID: 28148280 DOI: 10.1186/s13063-017-1777-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
397 Duong N, Curley K, Brown A, Campanelli A, Do MA, Levy D, Tantry A, Marriott G, Lu B. Decoy exosomes as a novel biologic reagent to antagonize inflammation. Int J Nanomedicine 2019;14:3413-25. [PMID: 31190800 DOI: 10.2147/IJN.S196975] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
398 Chen CB, Abe R, Pan RY, Wang CW, Hung SI, Tsai YG, Chung WH. An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. J Immunol Res 2018;2018:6431694. [PMID: 29651444 DOI: 10.1155/2018/6431694] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 11.5] [Reference Citation Analysis]
399 Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver 2017;11:55-61. [PMID: 27609485 DOI: 10.5009/gnl16041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
400 Dubinsky MC, Mendiolaza ML, Phan BL, Moran HR, Tse SS, Mould DR. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity. Inflamm Bowel Dis 2022:izab285. [PMID: 34978325 DOI: 10.1093/ibd/izab285] [Reference Citation Analysis]
401 Lonberg N. Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol 2008;:69-97. [PMID: 18071942 DOI: 10.1007/978-3-540-73259-4_4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
402 Bor R, Farkas K, Fábián A, Bálint A, Milassin Á, Rutka M, Matuz M, Nagy F, Szepes Z, Molnár T. Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease. PLoS One 2017;12:e0172916. [PMID: 28362851 DOI: 10.1371/journal.pone.0172916] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
403 Linares R, Francés R, Gutiérrez A, Juanola O. Bacterial Translocation as Inflammatory Driver in Crohn's Disease. Front Cell Dev Biol 2021;9:703310. [PMID: 34557484 DOI: 10.3389/fcell.2021.703310] [Reference Citation Analysis]